Resultados da pesquisa - safety after part phase rate

Pesquisas alternativas:
after part » after pars (Expandir a Pesquisa), after pain (Expandir a Pesquisa), after pap (Expandir a Pesquisa)
part phase » parent phase (Expandir a Pesquisa), gait phase (Expandir a Pesquisa), last phase (Expandir a Pesquisa)
phase rate » phase route (Expandir a Pesquisa), phase rule (Expandir a Pesquisa), phase role (Expandir a Pesquisa)

41

Prospective Phase II trial of drug-eluting bead chemoembolization for liver transplant candidates with hepatocellular carcinoma and marginal hepatic reserve

Prospective Phase II trial of drug-eluting bead chemoembolization for liver transplant candidates with hepatocellular carcinoma and marginal hepatic reserve

Por Fidelman, Nicholas, Johanson, Curt, Kohi, Maureen P, Kolli, K Pallav, Kohlbrenner, Ryan M, Lehrman, Evan D, Taylor, Andrew G, Kelley, R Kate, Yao, Francis Y, Roberts, John P, Kerlan, Robert K
Publicado no J Hepatocell Carcinoma (2019)

“... as a part of Stage 1 of a prospective single-institution Phase II trial. All patients had marginal...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

42

Efficacy, Safety, and Tolerability of Gepotidacin (GSK2140944) in the Treatment of Patients with Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections

Efficacy, Safety, and Tolerability of Gepotidacin (GSK2140944) in the Treatment of Patients...

Por O'Riordan, William, Tiffany, Courtney, Scangarella-Oman, Nicole, Perry, Caroline, Hossain, Mohammad, Ashton, Teri, Dumont, Etienne
Publicado no Antimicrob Agents Chemother (2017)

“...). This phase 2, randomized, 2-part, multicenter, dose-ranging, response-adaptive study with optional...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

43

Prognostic value of baroreflex sensitivity testing after acute myocardial infarction.

Prognostic value of baroreflex sensitivity testing after acute myocardial infarction.

Por Farrell, T G, Odemuyiwa, O, Bashir, Y, Cripps, T R, Malik, M, Ward, D E, Camm, A J
Publicado em 1992

“... with measures of autonomic function and to assess the safety of arterial baroreflex testing early after...”
Obter o texto integral
Obter o texto integral

Artigo

44

Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study

Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study

Por Tebib, Jacques, Mariette, Xavier, Bourgeois, Pierre, Flipo, René-Marc, Gaudin, Philippe, Le Loët, Xavier, Gineste, Paul, Guy, Laurent, Mansfield, Colin D, Moussy, Alain, Dubreuil, Patrice, Hermine, Olivier, Sibilia, Jean
Publicado em 2009

“... patient withdrawal rate observed can be partly attributed to a highly cautious response to adverse events...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

45

Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial

Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial

Por Scheithauer, Werner, Ramanathan, Ramesh K., Moore, Malcolm, Macarulla, Teresa, Goldstein, David, Hammel, Pascal, Kunzmann, Volker, Liu, Helen, McGovern, Desmond, Romano, Alfredo, Von Hoff, Daniel D.
Publicado no J Gastrointest Oncol (2016)

“...BACKGROUND: Dose modifications following adverse events (AEs) are an important part...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

46

A Phase Ib/II Study Evaluating the Combination of Weekly Docetaxel and Cisplatin Together with Capecitabine and Bevacizumab in Patients with Advanced Esophago-Gastric Cancer

A Phase Ib/II Study Evaluating the Combination of Weekly Docetaxel and Cisplatin Together...

Por Brenner, Baruch, Sarfaty, Michal, Purim, Ofer, Kundel, Yulia, Amit, Limor, Abramovich, Amir, Sadeh Gonik, Udi, Idelevich, Efraim, Gordon, Noa, Medalia, Gal, Sulkes, Aaron
Publicado no PLoS One (2016)

“... and cisplatin in AVDCX (phase Ib part) and to determine the tumor response rate (phase II part). RESULTS...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

47

Impact of source data verification on data quality in clinical trials: an empirical post hoc analysis of three phase 3 randomized clinical trials

Impact of source data verification on data quality in clinical trials: an empirical post hoc analysis of three phase 3 randomized clinical trials

Por Andersen, Jeppe Ragnar, Byrjalsen, Inger, Bihlet, Asger, Kalakou, Faidra, Hoeck, Hans Christian, Hansen, Gitte, Hansen, Henrik Bo, Karsdal, Morten Asser, Riis, Bente Juel
Publicado no Br J Clin Pharmacol (2015)

“... importance to efficacy or safety. CONCLUSIONS: The findings challenge the notion that a 0% error rate...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

48

Long-Term Follow-Up of a Phase I/II Study of ProSavin, a Lentiviral Vector Gene Therapy for Parkinson's Disease

Long-Term Follow-Up of a Phase I/II Study of ProSavin, a Lentiviral Vector Gene Therapy for Parkinson's Disease

Por Palfi, Stéphane, Gurruchaga, Jean Marc, Lepetit, Hélène, Howard, Katy, Ralph, G. Scott, Mason, Sarah, Gouello, Gaëtane, Domenech, Philippe, Buttery, Philip C., Hantraye, Philippe, Tuckwell, Nicola J., Barker, Roger A., Mitrophanous, Kyriacos A.
Publicado no Hum Gene Ther Clin Dev (2018)

“... in the defined “off” Unified Parkinson's Disease Rating Scale part III motor scores, compared to baseline...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

49

Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-α in patients with metastatic melanoma

Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab...

Por Alrwas, Anas, Papadopoulos, Nicholas E., Cain, Suzanne, Patel, Sapna P., Kim, Kevin B., Deburr, Tawania L., Bassett, Roland, Hwu, Wen-Jen, Bedikian, Agop Y., Davies, Michael A., Woodman, Scott E., Hwu, Patrick
Publicado no Melanoma Res (2014)

“...The primary objective of this study was to determine the safety, toxicity, and maximum tolerated...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

50

Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non–Small-Cell Lung Cancer: AF-001JP

Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non–Small-Cell Lung Cancer: AF-001JP

Por Tamura, Tomohide, Kiura, Katsuyuki, Seto, Takashi, Nakagawa, Kazuhiko, Maemondo, Makoto, Inoue, Akira, Hida, Toyoaki, Yoshioka, Hiroshige, Harada, Masao, Ohe, Yuichiro, Nogami, Naoyuki, Murakami, Haruyasu, Kuriki, Hiroshi, Shimada, Tadashi, Tanaka, Tomohiro, Takeuchi, Kengo, Nishio, Makoto
Publicado no J Clin Oncol (2017)

“...) and overall survival (OS), patients from the phase II part of AF-001JP were followed up for approximately 3...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

51

Efficacy, safety, and tolerance of the non-ergoline dopamine
agonist pramipexole in the treatment of advanced Parkinson's disease:
a double blind, placebo controlled, randomised, multicentre study

Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment...

Por Pinter, M, Pogarell, O, Oertel, W
Publicado em 1999

“... of the unified Parkinson's disease rating scale (UPDRS) in the on "period" (2 hours after intake of study...”
Obter o texto integral
Obter o texto integral

Artigo

52

Long-Term Efficacy and Safety of Linagliptin in a Japanese Population with Type 2 Diabetes Aged ≥ 60 Years Treated with Basal Insulin: A Randomised Trial

Long-Term Efficacy and Safety of Linagliptin in a Japanese Population with Type 2 Diabetes Aged ≥ 60 Years Treated with Basal Insulin: A Randomised Trial

Por Araki, Eiichi, Unno, Yuriko, Tanaka, Yuko, Sakamoto, Wataru, Miyamoto, Yuki
Publicado no Adv Ther (2019)

“... diabetes (T2DM). METHODS: In this phase 4, randomised, placebo-controlled national study (part of a global...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

53

First-In-Human Study on Pharmacokinetics, Safety, and Tolerability of Single and Multiple Escalating Doses of Hepenofovir, a Novel Hepatic Targeting Prodrug of Tenofovir in Healthy Chinese Subjects

First-In-Human Study on Pharmacokinetics, Safety, and Tolerability of Single and Multiple...

Por Hong Zhang, Lei Gao, Jinfeng Lou, Min Wu, Hong Chen, Lizhi Yang, Jingrui Liu, Xiaoxue Zhu, Xiaojiao Li, Cuiyun Li, Meng Wang, Chengjiao Liu, Weibo Guo, Yuan Wang, Zhongqiang Gao, Lei Han, Daidi Wang, Weili Jin, Yanhua Ding
Publicado em 2022-05-01

“...: This phase Ia study included two parts: a double-blinded, randomized, placebo-controlled single-ascending...”
Obter o texto integral

Artigo

54

Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant

Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid...

Por Sandmaier, Brenda M., Khaled, Samer, Oran, Betül, Gammon, Guy, Trone, Denise, Frankfurt, Olga
Publicado no Am J Hematol (2017)

“... with poor outcome following allogeneic hematopoietic‐cell transplant (allo‐HCT). This two‐part, phase 1...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

55

$An Open-label, Dose-Escalation Phase 1 Study of anti-TYRP1 monoclonal antibody IMC-20D7S for patients with relapsed or refractory melanoma$

An Open-label, Dose-Escalation Phase 1 Study of anti-TYRP1 monoclonal antibody IMC-20D7S for patients with relapsed or refractory melanoma

Por Khalil, Danny N., Postow, Michael A., Ibrahim, Nageatte, Ludwig, Dale L., Cosaert, Jan, Kambhampati, Siva Rama Prasad, Tang, Shande, Grebennik, Dmitri, Kauh, John Sae Wook, Lenz, Heinz-Josef, Flaherty, Keith T., Hodi, F. Stephen, Lawrence, Donald P., Wolchok, Jedd D.
Publicado no Clin Cancer Res (2016)

“... and safety data. One patient experienced a complete response (CR). A disease control rate, defined as stable...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

56

Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial)

Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial)

Por Rinnerthaler, Gabriel, Gampenrieder, Simon Peter, Petzer, Andreas, Burgstaller, Sonja, Fuchs, David, Rossmann, Dieter, Balic, Marija, Egle, Daniel, Rumpold, Holger, Singer, Christian F., Bartsch, Rupert, Petru, Edgar, Melchardt, Thomas, Ulmer, Hanno, Mlineritsch, Brigitte, Greil, Richard
Publicado no BMC Cancer (2018)

“... ixazomib in combination with carboplatin on days 1, 8, and 15 in a 28-day cycle. The phase I part...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

57

Two-Year Safety and Efficacy Experience in Patients with Methotrexate-Resistant Active Rheumatoid Arthritis Treated with Etanercept and Conventional Disease-Modifying Anti-rheumatic Drugs in the Latin American Region

Two-Year Safety and Efficacy Experience in Patients with Methotrexate-Resistant Active Rheumatoid...

Por Machado, Daniel A., Guzman, Renato, Xavier, Ricardo M., Simon, Jesus A., Mele, Linda, Shen, Qi, Pedersen, Ronald, Kotak, Sameer, Vlahos, Bonnie
Publicado no Open Rheumatol J (2016)

“.... In both groups, after treatment modification was permitted, clinical response rates and improvements...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

58

A Randomized Clinical Trial to Assess the Efficacy and Safety of Real-Time Continuous Glucose Monitoring in the Management of Type 1 Diabetes in Young Children Aged 4 to <10 Years

A Randomized Clinical Trial to Assess the Efficacy and Safety of Real-Time Continuous Glucose...

Por Mauras, Nelly, Beck, Roy, Xing, Dongyuan, Ruedy, Katrina, Buckingham, Bruce, Tansey, Michael, White, Neil H., Weinzimer, Stuart A., Tamborlane, William, Kollman, Craig
Publicado em 2012

“... children aged 4 to 9 years with type 1 diabetes. RESEARCH DESIGN AND METHODS: After a run-in phase, 146...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

59

Assessing the safety, impact and effectiveness of RTS,S/AS01E malaria vaccine following its introduction in three sub-Saharan African countries: methodological approaches and study set-up

Assessing the safety, impact and effectiveness of RTS,S/AS01E malaria vaccine following its...

Por Nicolas Praet, Kwaku Poku Asante, Marie-Cecile Bozonnat, Elaine Jacqueline Akité, Patrick Odum Ansah, Laurence Baril, Owusu Boahen, Yolanda Guerra Mendoza, Valerie Haine, Simon Kariuki, Mathieu Lamy, Kenneth Maleta, Randy Mungwira, Latif Ndeketa, Abraham Oduro, Bernhards Ogutu, Fredrick Olewe, Martina Oneko, Mattéa Orsini, Francois Roman, Edith Roset Bahmanyar, Dominique Rosillon, Lode Schuerman, Valentine Sing’oei, Dianne J. Terlouw, Stéphanie Wéry, Walter Otieno, Jean-Yves Pirçon
Publicado em 2022-04-01

Assuntos: “...Safety...”
Obter o texto integral

Artigo

60

Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico

Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a...

Por López-Macías, Constantino, Ferat-Osorio, Eduardo, Tenorio-Calvo, Alejandra, Isibasi, Armando, Talavera, Juan, Arteaga-Ruiz, Oscar, Arriaga-Pizano, Lourdes, Hickman, Somia P., Allende, María, Lenhard, Kathy, Pincus, Steven, Connolly, Kevin, Raghunandan, Ramadevi, Smith, Gale, Glenn, Gregory
Publicado no Vaccine (2011)

“... in order to supply vaccine after the onset of a pandemic. The safety and immunogenicity of one or two doses...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo